Details for Patent: 11,033,626

Which drugs does patent 11,033,626 protect, and when does it expire?

Patent 11,033,626 protects BIJUVA and is included in one NDA.

This patent has one hundred and fifty-nine patent family members in twenty-one countries.

Summary for Patent: 11,033,626

Title:	Progesterone formulations having a desirable pk profile
Abstract:	This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
Inventor(s):	Cacace; Janice (St. Petersburg, FL), Persicaner; Peter H. R. (Boca Raton, FL), Thorsteinsson; Thorsteinn (West Palm Beach, FL), Sancilio; Frederick (Palm Beach Gardens, FL), Amadio; Julia (Boca Raton, FL), Bernick; Brian (Boca Raton, FL), Irani; Neda (Palm Beach Gardens, FL)
Assignee:	TherapeuticsMD, Inc. (Boca Raton, FL)
Application Number:	16/578,148
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 11,033,626

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	BIJUVA	estradiol; progesterone	CAPSULE;ORAL	210132-002	Dec 28, 2021		RX	Yes	No			Y			TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
Mayne Pharma	BIJUVA	estradiol; progesterone	CAPSULE;ORAL	210132-001	Oct 28, 2018		RX	Yes	Yes			Y			TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS

International Family Members for US Patent 11,033,626

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095619
Argentina	098160
Argentina	099872
Argentina	107022